Follow the company. Check the evidence.
Public records connected to stocks traded by Congress. See what changed, when it became public, and the original source.
LLY: Department of Veterans Affairs contract award
AMYVID_BETA AMYLOID IMAGING
2 congressional households disclosed purchases in the past 90 days. See the trades
Foreign-Trade Zone 72; Application for Subzone Expansion; Eli Lilly and Company; Brownsburg, Lebanon, and Whitestown, Indiana
A Notice notice explicitly mentions the company. Read the cited text for its role.
Public: Nov 2, 2026Original source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
LLY: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.
2 congressional households disclosed purchases in the past 90 days. See the trades
LLY: Financial results
Filed 8-K for an event or period dated 2026-10-29. Financial results.
2 congressional households disclosed purchases in the past 90 days. See the trades
LLY: third_quarter 2026 lobbying report
General Healthcare issues, including drug accessibility, importation and innovation policies.
Public: Oct 20, 2026, 8:13 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
LLY: third_quarter 2026 lobbying report
Health insurance accessibility. Artificial Intelligence in health care. Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access. CMS National Coverage Determination on Alzheimer's disease. Implementation of the Inflation Reduction Act. Drug pricing, coverage, value, access and quality. Prescription drug approval. Drug importation. 340 B. Intellectual property. Pharmaceutical supply chain issues and shortages. Transparency. Issues related to intellectual property protection and market access within current trade negotiations.
Public: Oct 20, 2026, 6:45 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
LLY: third_quarter 2026 lobbying report
Issues related to treatments for Alzheimers therapeutics. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program.
Public: Oct 20, 2026, 5:41 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
LLY: third_quarter 2026 lobbying report
International and domestic tax issues. Implementation of PL 119-21. 340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies. SAFE Drugs Act (HR6509/S3794). FDA actions on drug compounding and illicit drugs. Issues related to TrumpRX. Alzheimer's Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267). Issues related to drug pricing; Issues related to reimbursement of insulin products and obesity medications: Issues related to most favored nation pricing polices. Accelerated approval pathway; support for Alzheimer's diagnostics;
Public: Oct 20, 2026, 4:47 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
LLY: third_quarter 2026 lobbying report
Lobbying related to pharmaceutical policy Medicare & Medicaid payment and coverage issues, lobbying related to pharmaceutical policy federal budget issues
Public: Oct 20, 2026, 2:26 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
LLY: third_quarter 2026 lobbying report
Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs. Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs.
Public: Oct 20, 2026, 10:22 AM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
LLY: third_quarter 2026 lobbying report
A lobbying activity report was filed. Income and expenses are separate reporting measures and must not be added together.
Public: Oct 20, 2026, 1:04 AM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
LLY: third_quarter 2026 lobbying report
Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products.
Public: Oct 19, 2026, 3:53 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
LLY: third_quarter 2026 lobbying report
Issues related to the pharmaceutical industry Treat and Reduce Obesity Act Pharmaceutical tariffs Safe Drugs Act Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain
Public: Oct 16, 2026, 7:21 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
LLY: third_quarter 2026 lobbying report
There is no specific bill filed. Engagement relates to issues on healthcare and trade. There is no specific bill filed. Engagement relates to issues on healthcare and trade.
Public: Oct 16, 2026, 6:33 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
LLY: third_quarter 2026 lobbying report
Issues related to healthcare Issues related to trade
Public: Oct 16, 2026, 1:01 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
LLY: third_quarter 2026 lobbying report
Monitored Issues and advised clients on matters related to Pharmaceutical supply chain security and resiliency.
Public: Oct 14, 2026, 11:16 AM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
LLY: third_quarter 2026 lobbying report
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality Pharmaceutical intellectual property issues Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU,
Public: Oct 12, 2026, 2:13 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
Foreign-Trade Zone (FTZ) 93, Notification of Proposed Production Activity; Eli Lilly and Company; (Drug Products); Durham, North Carolina
A Notice notice explicitly mentions the company. Read the cited text for its role.
Public: Sep 25, 2026Original source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
Foreign-Trade Zone (FTZ) 57, Notification of Proposed Production Activity; Eli Lilly and Company; (Drug Products); Concord, North Carolina
A Notice notice explicitly mentions the company. Read the cited text for its role.
Public: Sep 25, 2026Original source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
Granting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
A Notice notice explicitly mentions the company. Read the cited text for its role.
Public: Sep 17, 2026Original source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
LLY: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-06-30. Read the company report for its disclosures.
2 congressional households disclosed purchases in the past 90 days. See the trades
LLY: Financial results
Filed 8-K for an event or period dated 2026-08-05. Financial results.
2 congressional households disclosed purchases in the past 90 days. See the trades
Granting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
A Notice notice explicitly mentions the company. Read the cited text for its role.
Public: Jul 21, 2026Original source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
LLY: second_quarter 2026 lobbying report
Drug importation, prescription drug safety, value and access. International and domestic tax issues. Implementation of PL 119-21. 340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies. SAFE Drugs Act (HR6509/S3794). Issues related to drug pricing; Issues related to reimbursement of insulin products and obesity medications: Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices. Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment. Monitor Issues related t
Public: Jul 20, 2026, 3:04 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
LLY: second_quarter 2026 lobbying report
Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products.
Public: Jul 20, 2026, 1:54 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
Connections describe public records, not evidence of wrongdoing or a prediction of returns. Event dates can precede publication by days or months. When a source has no public-release timestamp, we show when we first observed it.
Source coverage
Coverage is growing across companies already tracked here. A scan can return no matching records. This feed is not a complete record of every filing or agency action.
- SEC EDGAR
- Current across tracked companies505 of 505 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:36 PM EST
- USAspending
- Collection in progress68 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:27 PM EST
- SAM.gov
- Awaiting company connections
- Lobbying disclosures
- Not yet scanned0 of 548 companies scanned in the past 12 hours
- Congress.gov
- Current across tracked companies5 of 5 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:39 PM EST
- Federal Register
- Collection in progress295 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:39 PM EST
- Regulations.gov
- Partial coverage — some requests unavailable33 of 53 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:39 PM EST
- FEC campaign finance
- Stale — refresh overdue0 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 11, 2026, 1:28 PM EST